Medicines and Healthcare products Regulatory Agency

Clinical Trials Directive (2001/20/EC) - Implementation in the UK

Dr Brian Davis

MHRA
Medicines and Healthcare products Regulatory Agency

The Clinical Trials Directive

- What is it about?
- How did the UK implement it?
- What difference does it make?
- What are the transitional arrangements?

Aims and Provisions of the Directive

- Ensure that the rights, safety and well-being of those participating in clinical trials are protected by:
  - Standardisation of procedures for ethical and competent authority consideration and authorisation
  - Setting good clinical practice (GCP) standards for commencing and conducting clinical trials;
  - Setting good manufacturing practice (GMP) standards for investigational medicinal products; and
  - Requiring inspections against internationally accepted principles and standards of GCP and GMP, supported by powers of enforcement.


EC COMMISSION GUIDELINES
GCP PRINCIPLES
ETHICS COMM APPLICATIONS
COMP AUTH APPLICATIONS
EUDRACT DATABASE
EUDRAVIGILANCE DATABASE
PHARMACO-VIGILANCE
COMMISSION AD HOC GROUP
REQUIREMENTS FOR MANFACTURE & IMPORT
APPLICATION FOR MANUFACTURE & IMPORT
PRINCIPLES OF GMP & ANNEX 13
GCP INSPECTION PROCEDURES
QUALIFICATIONS OF INSPECTORS
TRIAL MF & ARCHIVING
INSPECTORS WG

Transposing the Directive

Procedure

- Consultation: 21 Feb 03 for 12 weeks
- Consider comments
- Prepare Statutory Instrument
- Came into force 1May 2004
- Parliamentary Procedure
- Transitional arrangements

STATUTORY INSTRUMENTS

2004 No. 1031

MEDICINES

The Medicines for Human Use (Clinical Trials) Regulations 2004

Made - - - -	*31st March 2004*
Laid before Parliament	*1st April 2004*
Coming into force - -	*1st May 2004*


SCHEDULES
MISCELLANEOUS PROVISIONS
GENERAL PROVISIONS
INTRODUCTORY PROVISIONS
ENFORCEMENT & RELATED PROVISIONS
UK IMPLEMENTING REGULATIONS
ETHICS COMMITTEES
LABELLING OF IMPs
AUTHORISATION OF CLINICAL TRIALS AND EC OPINION
MANUFACTURE AND IMPORTOF IMPs
GCP AND THE CONDUCT OF CLINICAL TRIALS
PHARMACOVIGILANCE

New UK Regulatory Activities

- The Regulations introduce:
  - Written allocation of sponsor responsibilities for the management of clinical trials;
  - Authorisation of clinical trials in healthy volunteers;
  - Authorisations for manufacture of Investigational Medicinal Products;
  - Sharing of clinical trials data and pharmacovigilance;
  - Submission of annual safety reports;
  - Statutory Inspections for standards of GMP and GCP;and
  - Enforcement of new criminal offences.

Changes to UK requirements

- Ethics committees on statutory basis
  - Single opinion for multicentre trials
  - Time limit for considering applications
- Conditions and principles of GCP
  - Persons not able to consent
  - Legal representative
  - Emergency research

Changes to UK requirements

- Applications to MHRA: IMPD
  - Product has a marketing authorisation in any EU MS:
    - » Used within indications of MA - SPC
    - » Used outside indications of MA - SPC
    - » Change of drug substance manufacture - Quality data
  - Product has a CTA in UK:
    - » cross-refer to existing data with permission
    - » provide new data since CTA

Changes to UK requirements

- Amendments
  - Amendments to clinical trial information
  - Urgent safety measures
  - Compulsory amendments
- Suspension and termination

Changes to UK requirements

- Pharmacovigilance reporting
- Eudravigilance database
- Annual safety update reports
- Exchange information on clinical trials and ADR reports with MS, Eu Com and EMEA

Changes to UK requirements

- Manufacturing and import of IMPs
- Inspect for GCP and GMP
- Fees

Transitional Arrangements

- Clinical trial authorisations
  - Before 1 May 04
    - » CTC, CTX, CTMP, DDX
  - From 1 May 04
    - » Roll over as CTA
- Healthy volunteer studies
  - Before 1 May 04
    - » Obtain CTX or DDX to roll over
    - » Apply for CTA from 1 April 04
  - After 1 May 04
    - » Obtain CTA

Summary

- Aims of the Directive
- Outline of Guidelines
- UK Implementation
- Outline of UK Regulations
- Changes to UK requirements
- Transitional arrangements